scispace - formally typeset
Journal ArticleDOI

Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

TLDR
For patients with schizophrenia who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective than switching to another newer atypicals antipsychotics.
Abstract
Objective: When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine. In this study, the authors compared switching to clozapine with switching to another atypical antipsychotic in patients who had discontinued treatment with a newer atypical antipsychotic in the context of the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation. Method: Ninety-nine patients who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the trials, primarily because of inadequate efficacy, were randomly assigned to open-label treatment with clozapine (N=49) or blinded treatment with another newer atypical antipsychotic not previously received in the trial (olanzapine [N=19], quetiapine [N= 15], or risperidone [N=16]).

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

TL;DR: A meta-analysis of randomised controlled trials to compare the effects of second-generation antipsychotic drugs in patients with schizophrenia provided data for individualised treatment based on efficacy, side-effects, and cost.
Journal ArticleDOI

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

TL;DR: Although the proportional use of second-generation antipsychotic drugs rose from 13% to 64% during follow-up, the gap in life expectancy between patients with schizophrenia and the general population did not widen between 1996 and 2006.
Journal ArticleDOI

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

TL;DR: An extensive literature review was conducted to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations for prespecified outcomes of interest.
Journal ArticleDOI

Neurobiology of schizophrenia.

TL;DR: In this paper, the authors identify proteins of candidate genetic risk factors for schizophrenia, including dysbindin, neuregulin 1, DAOA, COMT, and DISC1.
References
More filters
Journal ArticleDOI

The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

TL;DR: Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
Journal ArticleDOI

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

TL;DR: In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients.
Journal ArticleDOI

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

TL;DR: It is confirmed that treatment-resistant schizophrenic patients have more favorable outcomes when treated with clozapine rather than a typical antipsychotic, as reflected by Brief Psychiatric Rating Scale total score, categorical response rate, Scale for the Assessment of Negative Symptoms score, Simpson-Angus Rating Scale score, and compliance rate.
Related Papers (5)

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

Herbert Y. Meltzer, +87 more